14
total announcements
524748.BO · 15 min delayed
Link Pharma Chem Ltd
Link Pharma Chem Ltd has re-appointed Mr. Satish G. Thakur as Chairman and Whole-time Director for 3 years, effective from 24th June, 2026.
Link Pharma Chem Ltd
Link Pharma Chem Ltd has re-appointed Mr. Rishikesh Thakur as Managing Director for 3 years, effective from 24th September 2026.
Link Pharma Chem Ltd
Link Pharma Chem Ltd's 41st Annual General Meeting was held on August 20, 2026, with all resolutions passed with the requisite majority. The meeting was conducted through video conferencing, with 3 promoters and 44 public shareholders attending. The resolutions included the adoption of audited financial statements, appointment of a director, ratification of remuneration of cost auditors, and other ordinary resolutions.
Link Pharma Chem Ltd
Link Pharma Chem Ltd has announced the voting results of its 41st Annual General Meeting, where all resolutions were passed with the requisite majority. The company has also submitted the Scrutinizer's Report dated August 20, 2026, as per the SEBI LODR Regulations, 2015.
Link Pharma Chem Ltd
Link Pharma Chem Ltd held its 41st Annual General Meeting (AGM) on August 20, 2026, through video conferencing. The meeting was attended by 47 members, including corporate representatives. The AGM considered and adopted the audited financial statements for the financial year ended March 31, 2026, and ratified the remuneration of the cost auditors for the financial year 2026-2027. The meeting also approved the re-appointment of Mr. Satish G. Thakur as a Chairman & Whole-time Director and Mr. Rishikesh Thakur as Managing Director. The Company Secretary informed the members about the availability of the Annual Report and the Register of Members, Directors, and Key Managerial Personnel for inspection.
Link Pharma Chem Ltd
Link Pharma Chem Ltd has published unaudited financial results for the quarter ended June 30, 2026, in newspapers as per SEBI listing regulations.
Link Pharma Chem Ltd
Link Pharma Chem Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹911.73 crore and total income at ₹911.73 crore. The company's expenses include cost of materials consumed, employee benefits expense, depreciation and amortization expense, and other expenses.
Link Pharma Chem Ltd
Link Pharma Chem Ltd announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹911.73 crore and expenses at ₹881.11 crore. The company's net profit for the quarter was ₹30.62 crore.
Link Pharma Chem Ltd
Link Pharma Chem Ltd dispatched a letter containing a web link of the Annual Report 2025-2026 to shareholders who have not registered their email addresses. The report is available on the company's website. The 41st Annual General Meeting (AGM) of the company is scheduled to be held on August 20, 2026, through video conferencing.
Link Pharma Chem Ltd
Link Pharma Chem Ltd has published a newspaper advertisement for its 41st Annual General Meeting (AGM) to be held on August 20, 2026, through video conferencing.
Link Pharma Chem Ltd
Link Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 05/08/2026 to consider and approve Unaudited Financial results for the quarter ended June 30, 2026.
Link Pharma Chem Ltd
Link Pharma Chem Ltd has announced the book closure for its 41st Annual General Meeting, with the register of members and share transfer books closed from August 14th to August 20th, 2026, for the purpose of the meeting on August 20th, 2026.
Link Pharma Chem Ltd
Link Pharma Chem Ltd submitted its Annual Report for FY 2025-2026 and notified the 41st AGM through Video Conferencing/OAVM on August 20, 2026. The AGM will consider the audited financial statements, appoint a director, ratify the cost auditor's remuneration, and appoint a secretarial auditor.
Link Pharma Chem Ltd
Link Pharma Chem Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on August 20, 2026, through video conferencing. The meeting will consider the audited financial statements for the year ended March 31, 2026, and the re-appointment of a director, among other items.